{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-303275","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.722289+00:00","generated_at":"2026-06-21T05:29:43.279084+00:00","sec_items":["5.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Magenta reports MGTA-117 Phase 1/2 data: no DLTs, two patients became transplant eligible","bullets":["MGTA-117 showed dose-dependent binding and depletion of CD117+ cells; no dose-limiting toxicities observed in 15 patients across Cohorts 1-3.","Two relapsed/refractory AML/MDS patients became eligible for transplant after a single dose of MGTA-117.","Phase 1/2 trial currently enrolling Cohort 4 (0.13 mg/kg); aggregate data including Cohort 4 expected Q1 2023.","Company plans to transition MGTA-117 into transplant-eligible AML/MDS patients in H1 2023 pending regulatory alignment.","MGTA-145 Phase 2 trial in sickle cell disease data now expected H1 2023 due to enrollment delays."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-303275","json":"https://secwatch.observer/filing/0001193125-22-303275.json","markdown":"https://secwatch.observer/filing/0001193125-22-303275.md","text":"https://secwatch.observer/filing/0001193125-22-303275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312522303275/0001193125-22-303275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312522303275/d434402d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:29:43.279084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}